GlassScriptPhysician profile
Robert J Paeglow
NPI 1568576379
$9,648.53
in general payments reported to CMS, 2019-2025
48 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $1,074 · 2021: $1,792 · 2022: $1,432 · 2023: $1,270 · 2024: $1,421 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,291.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,086.85 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,038.41 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $946.04 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $679.99 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $549.02 | 2022-2025 | |
| Indivior INC. | $464.63 | 2019-2025 | Sublocade |
| Lilly USA, LLC | $379.55 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.44 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $347.09 | 2021-2025 | Rexulti |
| Astellas Pharma US INC | $295.17 | 2020-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $279.32 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $278.27 | 2019-2025 | |
| Allergan, INC. | $223.31 | 2019-2020 | |
| Amgen INC. | $179.50 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $175.91 | 2022-2025 | Gardasil 9, Gardasil, Vaxelis |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $164.30 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $161.00 | 2021-2024 | Keveyis |
| Neurocrine Biosciences, INC. | $148.34 | 2019-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $139.47 | 2024-2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $139.46 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.38 | 2025 | Caplyta |
| Lundbeck LLC | $136.61 | 2023-2025 | Rexulti |
| Dexcom, INC. | $123.90 | 2022-2024 | Dexcom G6 Transmitter |
| Braeburn INC. | $114.59 | 2023-2024 | Brixadi |
| Collegium Pharmaceutical, INC. | $103.07 | 2021-2024 | Xtampza |
| Viatris Specialty LLC | $90.96 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $88.36 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.03 | 2019-2024 | Trulance, Xifaxan |
| Novartis Pharmaceuticals Corporation | $75.16 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $68.94 | 2021-2022 | |
| Alkermes, INC. | $66.03 | 2020-2024 | Aristada, Lybalvi |
| Orexo US, INC. | $51.70 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $51.69 | 2020-2021 | |
| Renalytix Ai, INC. | $46.46 | 2022-2023 | Kidneyintelx Blood Collection Convenience Kit |
| Kowa Pharmaceuticals America, INC. | $40.48 | 2022-2024 | Seglentis, Livalo, Zoryve |
| Exact Sciences Corporation | $39.32 | 2023-2024 | Cologuard Collection Kit |
| Eisai INC. | $37.46 | 2021 | |
| Ardelyx, INC. | $33.72 | 2025 | Ibsrela |
| Mylan Specialty L.P. | $30.87 | 2020-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $30.37 | 2023 | Spravato |
| Verona Pharma, INC. | $27.62 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $27.48 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $24.97 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $22.04 | 2023 | Quviviq |
| Exeltis, USA INC. | $20.10 | 2025 | Slynd |
| Horizon Therapeutics Plc | $17.50 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.65 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.00 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Paeglow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.